These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 25624880

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS.
    Cancer Res; 2006 Apr 01; 66(7):3386-91. PubMed ID: 16585158
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.
    Cecconetto L, Casadei Gardini A, Tenti E, Maltoni R, Bravaccini S, Oboldi D, Zoli W, Serra P, Donati C, Sarti S, Amadori D, Rocca A.
    Tumori; 2014 Apr 01; 100(3):e79-82. PubMed ID: 25076256
    [Abstract] [Full Text] [Related]

  • 28. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy.
    Sterba J, Pavelka Z, Andre N, Ventruba J, Skotakova J, Bajciova V, Bronisova D, Dubska L, Valik D.
    Pediatr Blood Cancer; 2010 Apr 01; 54(4):616-7. PubMed ID: 19967772
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y, Lee JL.
    Asia Pac J Clin Oncol; 2017 Jun 01; 13(3):204-211. PubMed ID: 27521286
    [Abstract] [Full Text] [Related]

  • 30. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Queralt F, Pezzotto SM, Rozados VR, Scharovsky OG.
    Cancer Chemother Pharmacol; 2016 Feb 01; 77(2):365-74. PubMed ID: 26721701
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B, André N, Barlesi F.
    Cancer Chemother Pharmacol; 2014 Sep 01; 74(3):647-52. PubMed ID: 25082520
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS, Shaked Y.
    Cancer Lett; 2017 Aug 01; 400():293-304. PubMed ID: 28202353
    [Abstract] [Full Text] [Related]

  • 39. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
    Sharma A, Malik PS, Khurana S, Kumar S, Bhatla N, Ray MD, Kumar L.
    Indian J Med Res; 2019 Dec 01; 150(6):575-583. PubMed ID: 32048620
    [Abstract] [Full Text] [Related]

  • 40. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D, André N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, Kutnikova L, Valik D, Sterba J.
    Oncology; 2012 Dec 01; 82(5):249-60. PubMed ID: 22538363
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.